Skip to main content

Research Repository

Advanced Search

Hematological malignancies in pregnancy

Allsup, David; Ali, Sahra; Robinson, Susan

Authors

Profile Image

Dr David Allsup D.J.Allsup@hull.ac.uk
Senior Lecturer in Haematology and Honorary Consultant

Sahra Ali

Susan Robinson



Contributors

David James
Editor

Philip Steer
Editor

Carl Weiner
Editor

Bernard Gonik
Editor

Stephen Robson
Editor

Abstract

The diagnosis of a hematological malignancy during pregnancy poses a major challenge to the pregnant woman, her family, and the medical team. Treatment of a pregnant woman with chemotherapy poses a risk to the fetus and raises therapeutic, ethical, and social dilemmas. A woman diagnosed with a hematological malignancy during pregnancy should be managed jointly by a multidisciplinary team comprising consultant hematologist, obstetrician, midwife, anesthesiologist, and neonatologist. Consideration should be given to the health of both mother and baby, with the informed wishes of the mother being considered paramount by the medical team. Psychological support should be offered to the woman and her family. Information giving should be supported by written information and a treatment plan. The woman should be fully informed about the diagnosis, her treatment options, potential complications, and the possible fetal and maternal outcomes.

Hematological malignancies can be broadly divided into myeloid and lymphoid tumors, according to the presumed cell of origin for each disorder. The incidences of myeloid and lymphoid hematological malignancies in the general population and summaries of the standard therapeutic approaches in the nonpregnant population are summarized in Tables 36.1 and 36.2.

• The myeloid tumors that will be considered in this chapter include:

– Acute myeloid leukemia (AML)

– Myelodysplastic syndromes (MDS)

– Myeloproliferative neoplasms (MPN)

– Chronic myeloid leukemia (CML)

• The lymphoid tumors to be considered include:

– Diffuse large B-cell lymphoma (DLBCL)

– Hodgkin lymphoma (HL)

– T-cell non-Hodgkin lymphoma (T-NHL)

– Follicular lymphoma (FL)

– Burkitt lymphoma (BL)

– Mantle cell lymphoma (MCL)

– Multiple myeloma (MM)

– Chronic lymphocytic leukemia (CLL)

Acute lymphoblastic leukemia (ALL), though technically a lymphoid tumor, is considered with AML because of commonalities in the approach to treatment.

Myeloid Tumors

Acute Leukemia

Acute leukemia diagnosed during pregnancy is uncommon, occurring in approximately 1 in 75,000– 100,000 pregnancies. AML represents approximately two-thirds and ALL one-third of cases.

The diagnosis of leukemia in pregnancy is more challenging than in nonpregnant individuals, since anemia and thrombocytopenia, which are common presenting features of acute leukemia, are common findings in pregnancy.

Citation

Allsup, D., Ali, S., & Robinson, S. (2017). Hematological malignancies in pregnancy. In D. James, P. Steer, C. Weiner, B. Gonik, & S. Robson (Eds.), High-Risk Pregnancy: Management Options (1006-1043). Cambridge University Press

Acceptance Date Oct 2, 2017
Online Publication Date Oct 2, 2017
Publication Date Oct 2, 2017
Deposit Date Apr 29, 2019
Publisher Cambridge University Press
Pages 1006-1043
Book Title High-Risk Pregnancy: Management Options
Chapter Number 36
Public URL https://hull-repository.worktribe.com/output/1674595
Publisher URL https://www.cambridge.org/core/books/highrisk-pregnancy-management-options/hematological-malignancies-in-pregnancy/6D33C112604CEAC62AE2559D07B61905